← Browse by Condition
Medical Condition
liver cancer
Total Trials
16
Recruiting Now
16
Trial Phases
Phase 2, Phase 4, Phase 1
Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.
Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.
The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.
Frequently Asked Questions — liver cancer Clinical Trials
How many clinical trials are currently recruiting for liver cancer?
ClinicalMetric currently tracks 16 actively recruiting clinical trials for liver cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 16. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for liver cancer?
liver cancer research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a liver cancer clinical trial?
Eligibility criteria for liver cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 1
Phase 2 2
Phase 4 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT05146297
Recruiting
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
Enrollment
644 pts
Location
United States
Sponsor
Icahn School of Medicine at Mo...
NCT06139042
Recruiting
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
Enrollment
1,608 pts
Location
China
Sponsor
Second Affiliated Hospital, Sc...
NCT07145801 Phase 2
Recruiting
Y-90 Treatment Response Using Transarterial Radioembolization
Enrollment
30 pts
Location
United States
Sponsor
Thomas Jefferson University
NCT07295275
Recruiting
Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
Enrollment
200 pts
Location
China
Sponsor
West China Hospital
NCT06084234 Phase 4
Recruiting
National Liver Cancer Screening Trial
Enrollment
5,500 pts
Location
United States
Sponsor
University of Texas Southweste...
NCT06084299 Phase 1
Recruiting
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
Enrollment
16 pts
Location
China
Sponsor
Zhiyong Huang
NCT07325565
Recruiting
Impact of Emotional Disorders on Response to Immune Checkpoint Inhibitor Therapy in Liver Cancer
Enrollment
651 pts
Location
China
Sponsor
Tongji Hospital
NCT07327489
Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Enrollment
2,000 pts
Location
United States
Sponsor
Elephas
NCT06263088
Recruiting
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Enrollment
200 pts
Location
United States
Sponsor
Case Comprehensive Cancer Cent...
NCT04371042
Recruiting
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Enrollment
5,000 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
NCT06681233
Recruiting
Feasibility Study of CBCT for IGRT in Cancer Patients
Enrollment
50 pts
Location
United States
Sponsor
Varian, a Siemens Healthineers...
NCT05184790
Recruiting
LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
Enrollment
300 pts
Location
Australia
Sponsor
University of Sydney
NCT07010315
Recruiting
Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
Enrollment
40 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06580002 Phase 2
Recruiting
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Enrollment
51 pts
Location
United States
Sponsor
University of California, Irvi...
NCT03844399
Recruiting
(3D) Ultrasound Imaging Liver and Kidney
Enrollment
40 pts
Location
Canada
Sponsor
Western University, Canada
NCT05850130
Recruiting
Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients
Enrollment
182 pts
Location
France
Sponsor
GERCOR - Multidisciplinary Onc...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology